ClinicalTrials.gg
RecruitingNCT07206823Updated Dec 4, 2025

Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia

An interventional study of Romiplostim N01 and Rituximab in Primacy Immune Thrombocytopenia, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by The First Affiliated Hospital of Soochow University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Planned enrollment
21st of 29
30 · median 62
Started
2025
the only one that year
No phase
2 of 29
2 open now
Registered
27th of 29
by date
Lead sponsor
2 of 29
The First Affiliated Hospital of Soochow University

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 21st largest by planned enrollment, is the only one that started in 2025, is one of 2 with no phase, and was the 27th registered.

Purpura, Thrombocytopenic, Idiopathic

505 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 160 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (47%) set no upper age limit and 43 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The primary objective of this trial is to assess the efficacy and safety of combining Romiplostim N01 with Rituximab for the treatment of adult patients with primary immune thrombocytopenia (ITP) whose disease is refractory to oral TPO-RAs.

All participants in this study will receive the same combination treatment:

Rituximab: Given once a week through an intravenous infusion for 4 weeks. Romiplostim N01: Given as a weekly injection,the dose may be adjusted each week based on the patient's platelet count.

Participants will be asked to:

Visit the clinic regularly for check-ups, blood tests (to monitor platelet counts), and safety assessments.

Report their bleeding symptoms for evaluation. This is an open-label, single-arm trial, meaning that all participants will receive the investigational treatment, and both the research team and participants will be aware of the treatment assigned. The study aims to enroll approximately 30 adult patients aged 14 years or older who have been diagnosed with ITP and have not responded adequately to prior oral TPO-RAs (eltrombopag/hetrombopag).

03

Conditions studied

  • Primacy Immune Thrombocytopenia
04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Confirmed diagnosis of primary immune thrombocytopenia (ITP).

Age ≥14 years.

Prior exposure to at least one ITP-directed therapy (e.g., , intravenous immunoglobulin, recombinant human thrombopoietin, TPO-RAs, , or splenectomy), including a minimum 4-week course of an oral TPO-RA (hetrombopag or eltrombopag) that was discontinued due to insufficient response.

count \< 30 × 10⁹/L at screening, OR platelet count \< 50 × 10⁹/L with concurrent bleeding.

Stable glucocorticoid dose (e.g., prednisone or methylprednisolone, not exceeding 4 tablets daily) for at least 2 weeks, and stable dosing of any other immunosuppressants for at least 4 weeks prior to enrollment.

No receipt of intravenous immunoglobulin within 2 weeks before the first dose of study treatment.

No platelet transfusion within 1 week before the first dose of study treatment.

Exclusion criteria

Exclusion Criteria:

Secondary ITP due to underlying conditions such as other disorders, viral infections, or drug exposure.

Presence of active , pregnancy, significant cardiovascular or cerebrovascular disease, or history of arterial/venous thrombosis.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Romiplostim N01 + Rituximab Combination Therapy

    Drug: Romiplostim N01 · Drug: Rituximab

Interventions

  • DrugRomiplostimStudies of RomiplostimRomiplostim pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Romiplostim N01 will be administered via subcutaneous injection once weekly based on the platele count. The starting dose is set at 3 μg/kg. Weekly dose adjustments will be guided by platelet counts measured immediately prior to administration, as follows: For a platelet count below 50 × 10⁹/L, the dose will be increased by 1 μg/kg. For a platelet count between 50 and 200 × 10⁹/L, the current dose will be maintained as the minimum therapeutic dose for bleeding risk reduction. For a platelet count between 200 and 400 × 10⁹/L, the dose will be decreased by 1 μg/kg. For a platelet count exceeding 400 × 10⁹/L, the administration will be withheld. It is stipulated that dosing will resume at a reduction of 1 μg/kg from the previous dose once the platelet count returns to 200 × 10⁹/L or below. Under no circumstances shall the dose exceed the maximum allowable limit of 10 μg/kg per week.

  • Rituximab will be administered in accordance with the Chinese guidelines for the diagnosis and management of adult primary immune thrombocytopenia (2020 edition). The dosage will be 375 mg/m² per infusion, administered via intravenous infusion once weekly for a total of four weeks.

06

What researchers measure

Primary outcomes

  1. Efficacy evaluation

    Efficacy assessments (platelet count) are performed weekly from Week 2 to Week 8, and then monthly until Month 12. Efficacy evaluation relies on time to platelet response, overall response rate, complete response rate and maintained response rate

    Time frame: from week 2 to month 12

  2. Incidence of severe Adverse Events

    Adverse events include the monitoring of the incidence of thrombotic events, myelofibrosis, and severe infections.

    Time frame: up to 12 months

Secondary outcomes

  1. Long-term Sustained Response Rate versus Relapse Rate

    Time frame: at 6 months and 12 months

  2. Proportion of Participants Achieving a Rapid Platelet Response

    Platelet count is assessed weekly during this period

    Time frame: within the first 8 weeks of treatment

  3. Change in Bleeding Score Over Time

    Time frame: up to 12 months

  4. Incidence of other adverse events

    Recording the incidence of other adverse events, such as liver and kidney dysfunction, and hypersensitivity reactions.

    Time frame: up to 12 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Oct 3, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Jul 31, 2027
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07206823
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Sep 1, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Dec 4, 2025

Study contacts

Hong Tian
Contact
tianhong0718@163.com
+86 0512 67781521

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Romiplostim · Rituximab

Start the discussion